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Background and Purpose: The potential for adaptive plasticity in the post-stroke brain
is difficult to estimate, as is the demonstration of central nervous system (CNS) target
engagement of drugs that show promise in facilitating stroke recovery. We set out to
determine if paired associative stimulation (PAS) can be used (a) as an assay of CNS
plasticity in patients with chronic stroke, and (b) to demonstrate CNS engagement by
memantine, a drug which has potential plasticity-modulating effects for use in motor
recovery following stroke.
Methods: We examined the effect of PAS in fourteen participants with chronic
hemiparetic stroke at five time-points in a within-subjects repeated measures design
study: baseline off-drug, and following a week of orally administered memantine at
doses of 5, 10, 15, and 20 mg, comprising a total of seventy sessions. Each week,
MEP amplitude pre and post-PAS was assessed in the contralesional hemisphere as a
marker of enhanced or diminished plasticity. Strength and dexterity were recorded each
week to monitor motor-specific clinical status across the study period.
Results: We found that MEP amplitude was significantly larger after PAS in baseline
sessions off-drug, and responsiveness to PAS in these sessions was associated with
increased clinical severity. There was no observed increase in MEP amplitude after PAS
with memantine at any dose. Motor threshold (MT), strength, and dexterity remained
unchanged during the study.
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Conclusion: Paired associative stimulation successfully induced corticospinal
excitability enhancement in chronic stroke subjects at the group level. However, this
response did not occur in all participants, and was associated with increased clinical
severity. This could be an important way to stratify patients for future PAS-drug studies.
PAS was suppressed by memantine at all doses, regardless of responsiveness to PAS
off-drug, indicating CNS engagement.
Keywords: paired associative stimulation, stroke, memantine, neurorehabilitation, TMS

Here, we examine the effect of memantine, a drug used
for treatment of Alzheimer’s disease, on the PAS response
in patients with chronic stroke. Memantine is described
pharmacologically as a low affinity, voltage dependent, noncompetitive, NMDA antagonist (Rogawski and Wenk, 2003).
At high concentrations, like other NMDA-R antagonists, it
can inhibit synaptic plasticity. At lower, clinically relevant
concentrations, memantine can, under some circumstances,
promote synaptic plasticity by selectively inhibiting extrasynaptic glutamate receptor activity while sparing normal
synaptic transmission, and hence may have clinical utility
for rehabilitation (Xia et al., 2010). Interest in specifically
using the drug for its interaction with stroke pathophysiology
stems from animal models of both prevention (Trotman
et al., 2015), in which pre-conditioning reduced infarct size,
as well as for functional recovery, in which chronic oral
administration starting >2 h post-stroke resulted in improved
function through a non-neuroprotective mechanism (LópezValdés et al., 2014). In humans, memantine taken over
multiple days has been used to demonstrate that the NMDA
receptor is implicated in specific transcranial magnetic pairedpulse measures (Schwenkreis et al., 1999), and short-term
training-induced motor map reorganization (Schwenkreis et al.,
2005). In studies of neuromodulation, memantine blocked
the facilitatory effect of intermittent theta-burst stimulation
(iTBS) (Huang et al., 2007). Similarly, LTP-like plasticity
induced by associative pairing of painful laser stimuli and
TMS over primary motor cortex (M1) can also be blocked by
memantine (Suppa et al., 2013). The effects of memantine on
the PAS response have not yet been demonstrated, including
examination of potential dose-response effects, which would be
important for the potential clinical application of memantine for
stroke recovery.
In our study, we set out to determine whether PAS
might be a useful tool to probe the potential for plasticity
after stroke in persons with chronic hemiparesis and
apply PAS as an assay to look at drug effects on motor
system plasticity using memantine. We hypothesized that
(a) PAS would enhance corticospinal excitability in the
contralesional hemisphere of stroke patients, and that (b)
since PAS-induced plasticity is thought to involve a shortterm change in glutamatergic synaptic efficacy, memantine
would have a dose-dependent effect on PAS response. We
predicted that at low doses, memantine would enhance PASinduced plasticity through selective blockade of extrasynaptic
NMDA receptors, whereas higher doses would inhibit
PAS-induced plasticity.

INTRODUCTION
The capacity of the brain to make structural, physiological,
and genetic adaptations following stroke, otherwise known as
plasticity, is likely to be critical for improving sensorimotor
impairments and functional activities. Promotion of adaptive
plasticity in the central nervous system (CNS) leading to
sustained functional improvement is of paramount importance,
given the personal suffering and cost associated with poststroke disability (Ma et al., 2014). In addition to rehabilitation
therapies to retrain degraded motor skills, animal and human
studies have tried to augment recovery with neuropharmacologic
interventions. Unfortunately, few if any have had a notable
effect in patients or have come into routine use (Martinsson
et al., 2007; Chollet et al., 2011; Cramer, 2015; Simpson et al.,
2015). Methods to screen drugs based on their presumed
mechanism of action on plasticity in human motor systems
could speed translation to patients. However, there is currently
no accepted method in stroke patients for evaluating the
potential effectiveness or individual responsiveness to putative
“plasticity enhancing” drugs in an efficient, low-cost, crosssectional manner, in order to establish target engagement in
humans and to avoid the extensive time and cost of protracted
clinical trials.
Paired associative stimulation (PAS) is a safe, painless,
and non-invasive technique known to result in short-term
modulation of corticospinal excitability in the adult human
motor system, lasting ∼90 min (Stefan et al., 2000; Wolters et al.,
2003). Post-PAS excitability enhancement has been considered
an LTP-like response thought to relate to transient changes in
synaptic efficacy in the glutamatergic system at the N-methylD -aspartate (NMDA) receptor, since both human NMDA
receptor deficiency (Volz et al., 2016) and pharmacological
manipulation with dextromethorphan (Stefan et al., 2002) can
block the effect. While PAS has been explored as a potential
therapeutic intervention in patients with residual motor deficits
after stroke (Jayaram and Stinear, 2008; Castel-Lacanal et al.,
2009), it has not previously been investigated for its potential
use as an assay of motor system plasticity in this context.
Prior studies have suggested that motor practice and PAS
share the same neuronal substrates, modulating LTP and LTDlike plasticity in the human motor system (Ziemann et al.,
2004; Jung and Ziemann, 2009); therefore, as an established
non-invasive human neuromodulation method (Suppa et al.,
2017), we reasoned that PAS would be a suitable assay in
the present study to examine the effect of a drug on motor
system plasticity.
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MEP assessment, stimulus intensity was set as follows: steps of
5% maximal stimulator output (MSO) commencing at 120%
MT, 3 pulses per intensity, ceasing when MEP peak-to-peak
amplitude increase reached a plateau (MEP max). The MTAT
tool was then used to adjust the stimulator intensity to obtain
an MEP amplitude representative of half of the participant’s
MEP max. Twelve TMS pulses were delivered for each resting
collection (pre/post-PAS) at ∼5–10 s intervals between pulses
over 1–2 min. Resting motor threshold (RMT) and TMS intensity
are reported as percentage of maximum stimulator output
(%MSO) hereafter.

MATERIALS AND METHODS
Participants
Participants enrolled in the study were aged ≥18 years,
with unilateral ischemic stroke at least 6 months prior, and
upper limb paresis (≥7 points on the Fugl-Meyer impairment
scale). Exclusion criteria were as follows: contraindications to
transcranial magnetic stimulation (TMS; seizure/epilepsy history,
pacemaker/other electro-sensitive implants), medications or
conditions that affect the metabolism of memantine, concurrent
pregnancy, hemorrhagic stroke, prior stroke, and co-existing
neurological disorders. Written informed consent was obtained
from all participants. The study had approval from the
Institutional Review Board of the Burke Rehabilitation Center.

Paired Associative Stimulation
Intervention
Ulnar nerve electrical stimulation (DS7AH Digitimer Ltd.,
United Kingdom) was delivered with surface electrodes (8 mm
diameter, 30 mm apart; Signa gel) positioned 3 cm above the
palmar wrist crease of the unaffected arm, with cathode proximal
(single 200 µs rectangular pulses). Perceptual threshold was
defined as the minimum perceivable stimulator intensity (mA).
The PAS protocol approximated that described by Player
et al. (2012), targeting the contralesional hemisphere, comprising
200 pairs of stimuli (TMS and ulnar nerve) given at 0.25 Hz
over 13 min (Ziemann et al., 2004). In each pair, ulnar nerve
stimulation (300% of perceptual threshold) preceded the TMS
pulse (130% MT) by 25 ms. Baseline MEPs were collected
immediately prior to the PAS intervention, followed by an
immediate repeat of baseline at time 0 post, then every 10 min
with a final recording at 60 min.

Study Design and Drug Administration

R

The purpose of this experiment was to explore the potential
of PAS to serve as a screening method for drugs of interest in
neurorehabilitation. We used a within-subject repeated measures
design to examine the effect of PAS in the contralesional
hemisphere of hemiparetic persons with chronic stroke, and to
test for a dose-effect of memantine on PAS response. Given the
variable nature of MEPs and inter-individual responsiveness to
neuromodulatory protocols, such a design is appropriate for this
study. Participants attended over 5 weeks, including a screening
visit and baseline assessment of clinical function and response to
PAS. After the first PAS assessment, participants were given 5 mg
of memantine, administered once daily for 1 week. The dosage
of memantine was increased every 7 days by 5 mg to: 10, 15, and
20 mg on the 5th week. The dose of memantine was increased
incrementally every week to assess for potential side effects with
increasing doses. PAS response was reassessed weekly a day prior
to the next dosing schedule, for a total of 5 PAS sessions per
participant. The criterion measure for within session effects of
PAS was MEP amplitude.

Clinical, Functional, and
Neurophysiological Evaluation Across
Weeks
An upper limb clinical impairment measure (Fugl-Meyer scale,
FM) and a functional assessment (Wolf motor function test)
were performed at the start and end of the study, in order to
capture clinical status post 4 weeks of incremental memantine
administration and PAS, relative to baseline.
Participants performed a weekly dexterity test (9-hole peg test,
single trial, total time, seconds) and a strength test (maximum
grip, mean of 3 trials, lbs.), with both the unaffected and the
affected hand, so as to capture any potential effects of brain
stimulation and drug on clinical function. Dexterity and strength
tests were performed at the scheduled clinic visit prior to the PAS
intervention. No upper extremity rehabilitation was provided.
RMT and sensory perceptual threshold were assessed weekly
to determine stimulator intensity for the PAS protocol.

Transcranial Magnetic Stimulation and
Electromyography
Participants were seated reclined with arms relaxed and
supported by a pillow, with surface EMG electrodes (Biometrics
Ltd., SX230 1000× gain) over the first dorsal interosseous (FDI)
muscle bilaterally, and ground electrode over the ulnar styloid.
Via a head stage (Biometrics Gwen+ NPII 7 Hz 8 Channel), EMG
was digitized at 5 kHz (Cambridge Electronic Design, Expansion
ADC12/CED Micro1401 MKII), and band-pass filtered (20–
1000 Hz; Spike 2, V7.15 CED). A Lycra cap with a 1 × 1 cm
coordinate system was centered over the vertex (intersection of
mid-point between nasion-inion and inter-aural lines). TMS was
administered over the contralesional hemisphere, with the coil
(Magstim Figure-8, double 70 mm) handle posterior and rotated
laterally 45◦ from the midline. All TMS was performed with
Magstim 2002 BiStim2 (Model 3010-00). The optimal site for FDI
was explored with three to four suprathreshold pulses at each grid
position commencing at C3/C4.
At each visit, motor threshold (MT) was calculated at rest,
using the MT assessment tool (Awiszus, 2003). For baseline

Frontiers in Neuroscience | www.frontiersin.org

Data Analysis
Motor Evoked Potential Processing
MEPs were visually inspected offline and analyzed for peak-topeak amplitude using Spike 2 software (Cambridge Electronic
Design, Cambridge, United Kingdom). The first two pulses
from each collection were routinely excluded, as were MEPs
with background EMG >25 µV within 100 ms prior to the
TMS stimulus. The median MEP amplitude was averaged across
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further evaluated the interaction between baseline responder
status and MEP amplitude increase post-PAS with the different
doses of memantine.

participants at each time point for the group analysis, repeated
for each dose of drug.

Statistical Analyses
We compared the mean MEP amplitude over the 1st hour postPAS intervention versus MEP amplitude immediately before
intervention (baseline), with a non-parametric rank-sum test for
paired differences, and a one-sided p-value of 0.05 testing for an
increase in amplitude with PAS, for the off-drug condition and
for each memantine dose.
We also explored each 10-min interval of the 1st hour
post-intervention, comparing mean absolute change in MEP
amplitude, and the proportion of participants who increased,
using two-sided exact binomial tests. This was again repeated for
each memantine dose.
To assess potential long-term effects of PAS or memantine,
we compared clinical measures at the start of the study to the
same assessments 1 week after the last dose, using the nonparametric rank-sum test for paired differences and a one-sided
p-value of 0.05.

RESULTS
Participant Clinical Characteristics
Fourteen participants with chronic hemiparetic stroke were
enrolled and completed the study (age range 48–91 years, four
female/ten male, 6–161 months post-ischemic stroke; see Table 1
for baseline clinical and neurophysiological characteristics at
study entry, and Figure 1 for imaging of lesion location). Upper
limb Fugl-Meyer impairment score at study entry ranged from 7
to 60 points (mean 32.7, out of a maximum possible 66 points).
PAS and memantine appeared to be safe and well tolerated by
all participants; there were no adverse events related to the study
medication or PAS.

Within-Session PAS Effects

Exploratory Responder Analysis

Paired
associative
stimulation
successfully
increased
corticospinal excitability in the contralesional hemisphere
in the baseline session without memantine. The mean MEP
amplitude was significantly higher after PAS intervention as
shown in Figures 2A,B (0.504 mV pre, 0.851 mV post, 0.346 mV
mean increase; 90% CI 0.055–0.638; one-sided p = 0.028, median
increase 0.364, one-sided p = 0.045; sample waveforms are shown
in Figure 3). The numerically largest increase in MEP amplitude
was seen 20 min post-intervention (Figure 2A), where 85.7% of
participants had increased MEP amplitude (one-sided p = 0.013),
and 78.5% had increased by at least 10% (one-sided p < 0.001).
With all doses of memantine (5–20 mg), there was no
significant increase in MEP amplitude after PAS at the group
level, suggesting that memantine blocked synaptic plasticity at the

In secondary analyses, we stratified participants into PAS
responders and non-responders according to their response
to PAS in the baseline session (off-drug), as per MüllerDahlhaus et al. (2015) and Strube et al. (2015), where responders
were defined as subjects exhibiting a post-intervention MEP
amplitude increase of >10% from baseline. We evaluated
clinical and neurophysiological features that were associated
with having a response to PAS. Interhemispheric difference
in corticospinal excitability was calculated by subtracting the
ipsilesional hemisphere RMT value from the contralesional
hemisphere RMT value for each subject. A RMT value of 100
was assigned for cases in which RMT was unable to be derived
from the ipsilesional hemisphere (Stinear et al., 2015). We

TABLE 1 | Participant characteristics at study entry.
ID

Time since onset (months)

FM-UE

WMFT (s)

rMT (%MSO)
U

A

Medication

P1

18

7

1613.9

47

NR

Insulin, albuterol, tamsulosin

P2

94

19

1367.1

53

NR

ASA, simvastatin, levetiracetam, levothyroxine, alendronic acid

P3

28

14

1802.6

54

NR

ASA, escitalopram

P4

100

30

674

43

NR

ASA, lisinopril

P5

27

48

54.3

48

NR

Losartan, nebivolol, atorvastatin, sertraline

P6

46

20

1452.5

55

NR

ASA, atorvastatin, escitalopram

P7

64

7

1448.1

42

NR

ASA, amlodipine, simvastatin, tamsulosin, escitalopram

P8

161

50

35.3

53

61

Warfarin, metoprolol, lisinopril, digoxin, simvastatin, metformin

P9

80

34

56.7

49

51

ASA, lisinopril, simvastatin, tamsulosin, dutasteride

P10

35

53

30.6

43

48

ASA, carvedilol, quinapril, HCTZ, atorvastatin

P11

28

48

36.3

33

34

Apixaban, sotalol, atorvastatin, pantoprazole, citalopram, gabapentin, trazodone

P12

149

24

1565.7

49

46

Clopidogrel, atorvastatin, oxybutynin, hydrocodone

P13

6

60

27.9

44

64

ASA, atorvastatin, fluoxetine, baclofen

P14

20

44

65.6

35

53

ASA, atenolol, amlodipine-benazepril, atorvastatin, duloxetine, gabapentin

FM-UE, Fugl-Meyer Upper Extremity; WMFT, Wolf Motor Function Test; rMT, resting Motor Threshold; MSO, Maximum Stimulator Output; U, Unaffected Hemisphere; A,
Affected Hemisphere; NR, No Response; ASA, Aspirin; HCTZ, Hydrochlorothiazide.
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FIGURE 1 | Axial MR/CT images for individual patients illustrating the stroke lesion. Images are displayed in radiological convention. Images are labeled by
participant number.

range of doses tested, contrary to our prediction that low doses
would enhance PAS-induced plasticity. In the 5 mg condition1
(Figure 4A), MEP amplitude was not increased from baseline
following PAS intervention (0.589 mV pre, 0.597 mV post,
0.009 mV mean increase; 90% CI −0.174–0.191; p = 0.467;
median increase 0.0001, p = 0.620). With 10 mg memantine
(Figure 4B), MEP amplitude was again not found to increase
from baseline (0.622 mV pre, 0.728 mV post, 0.106 mV mean
increase; 90% CI −0.046–0.258; p = 0.119; median increase 0.078,
p = 0.195). Similarly, MEP amplitude was not increased from
baseline with 15 mg memantine (Figure 4C; 0.594 mV pre,
0.794 mV post, 0.200 mV mean increase; 90% CI -0.014-0.414;
p = 0.061; median increase 0.164, p = 0.077) or with 20 mg
memantine (Figure 4D; 0.642 mV pre, 0.642 mV post, 0.001 mV
mean increase; 90% CI -0.181-0.181; p = 0.499; median increase
0.001, p = 0.548).

Clinical, Functional, and
Neurophysiological Assessment Across
Weeks
We did not observe significant changes between the first and
last week of intervention in RMT in the ipsilesional hemisphere
(n = 7 evaluable, average change-0.71%MSO [90%CI –2.64,
1.22], p = 0.750) nor in the contralesional hemisphere (n = 14,
−0.61[3.27, 2.04], p = 0.656). We also observed no significant
changes in clinical measures of grip strength (1.43lbs [−2.59,
5.44], p = 0.270; affected n = 11, 4.54 [1-0.76, 10.85], p = 0.11
unaffected, n = 14), dexterity as measured with the 9 hole peg test
(−0.61s [−3.27, 2.04], p = 0.656 affected n = 6, 10.93 [−32.07,
53.94], p = 0.315 unaffected n = 14), or sensory perceptual
threshold (0.350 mA [−0.375, 1.075], p = 0.204).

Exploratory Responder Analysis

FIGURE 2 | MEP amplitude is significantly increased post-PAS intervention
relative to pre-PAS amplitude in the baseline off-drug session. Data are shown
depicting MEP amplitude change from baseline for individual time-points
post-PAS (A) and mean MEP amplitude for pre and the hour post-PAS (B).

Eight of fourteen participants were classified as responders
to PAS, defined as subjects exhibiting a post-PAS MEP
amplitude increase of >10%. Responders had a mean postPAS increase of >200% in MEP amplitude (post/pre ratio,

2.23 [1.82; 3.33] Figure 5). The responders were clinically
more severe as shown by increased time on the Wolf Motor
Function Test (responder, mean = 1450 ± 719 SD sec;

1

We conservatively removed one subject from analysis at 5 mg where the median
MEP value at baseline was <50 µV, who therefore showed a disproportionately
high response at over 15-fold increase.
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FIGURE 3 | Representative MEP waveforms from a single participant pre and
post-PAS intervention. Peak-to-peak MEP amplitude was enhanced by PAS in
the baseline session.

non-responder, 46 ± 541, p = 0.028), lower grip strength
(responder, mean = 17.5 ± 13.3 SD lbs.; non-responder,
53 ± 27.5, p = 0.01), and TMS measures (six of eight
responders had no detectable MEP on the affected side;
versus one of six non-responders). Other clinical (FM) and
neurophysiological (RMT difference) measures were in the same
direction of greater severity, but were not statistically significant.
Baseline corticospinal excitability (RMT) in the contralesional
(intervention) hemisphere was comparable between responders
and non-responders (mean responder, 46.4 ± 7.1; mean nonresponder, 46.2 ± 6.9; median responder, 47.5 [42.8; 50.2];
median non-responder, 46.5 [43.2; 52.0] p = 1.00). There was
no significant interaction between responder status and the
mean increase in MEP amplitude post-PAS with any dose of
memantine (see Supplementary Table 1) (5 mg condition;
F = 0.450, p = 0.823, 10 mg condition; F = 1.681, p = 0.128,
15 mg condition; F = 2.296, p = 0.190, 20 mg condition;
F = 1.297, p = 0.295).

DISCUSSION
In the present study, we examined whether PAS MEPpotentiation could be a surrogate biomarker of the likelihood
that a particular medication at an optimal dose may augment
plasticity. If proven viable, this methodology would be invaluable
to the field, as there is currently no accepted method in stroke
patients for evaluating the potential effectiveness or individual
responsiveness to varying doses of putative ‘plasticity enhancing’
drugs in an efficient, low-cost, cross-sectional manner. This
would be the first step toward trials testing therapeutic drugs
in combination with training aimed at improving motor
skills after disabling stroke. PAS has received interest for
improving motor function post-stroke (Jayaram and Stinear,
2008; Castel-Lacanal et al., 2009), however, response to a single
application as a window into the capacity for human brain
plasticity has not been evaluated in this context. We showed
that without memantine, PAS resulted in an after-effect of
heightened excitability (MEP amplitude increase) consistent
with the literature in healthy adults (Stefan et al., 2000;

Frontiers in Neuroscience | www.frontiersin.org

FIGURE 4 | MEP change from baseline after PAS with 5 mg (A), 10 mg (B),
15 mg (C), and 20 mg (D) memantine. Group MEP amplitude over the 60 min
following PAS was not significantly increased from baseline, with any dose of
memantine.

Player et al., 2012). When participants were assessed following
1 week of memantine administration, at every dose evaluated (5–
20 mg), excitability remained at baseline levels post-intervention,
indicating that the PAS-induced excitability enhancement was
blocked by memantine as assessed at steady-state. Although the
predictive value of PAS for drug-induced functional recovery
post-stroke has yet to be established, our data suggest that,
while clinical doses of memantine can penetrate into the CNS
to affect function, we found no evidence that it enhances
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amplitude increase post-intervention may suggest an alternative
methodological approach for PAS application in post-stroke drug
dosing studies (responder analysis; see below).

Drug Selection
Our selection of the drug memantine was in part based on prior
studies in hippocampal microcultures by Lipton et al., (Xia
et al., 2010). We hypothesized that low doses of the clinically
approved, use-dependent glutamate antagonist, memantine
(5–10 mg), would enhance PAS-induced excitability in the
contralesional hemisphere via its ability to selectively block
extrasynaptic glutamate receptors, while leaving synaptic
glutamate receptors unperturbed. Extrasynaptic glutamate
activity has been hypothesized to block plasticity-associated
gene expression mediated via activation of synaptic glutamate
(Hardingham and Bading, 2010). Contrary to our hypothesis,
the current study showed that PAS-induced neuromodulation
in chronic stroke was abrogated at all doses of memantine. This
finding also favors a synaptic LTP-like mechanism for post-PAS
excitability enhancement, and is consistent with a separate study
using intermittent theta burst stimulation (iTBS) in healthy
human subjects, where memantine blocked the excitability
enhancing effect of iTBS (Huang et al., 2007). It remains possible
that synaptic plasticity would be enhanced with memantine at
lower doses (<5 mg) than those tested in this study. Additionally,
Ziemann et al. (2004) demonstrated that LTP-dependent motor
learning can block subsequent induction of LTP via PAS due to
homeostatic metaplasticity; therefore, LTP-like plasticity induced
by memantine could have blocked the effects of further LTP
induction via PAS. This can be tested in future experiments using
a LTD-like PAS protocol.

FIGURE 5 | MEP amplitude pre and post-PAS (0–60 min) for responders
(mean post >10% mean pre) and non-responders, off-drug (ratio post/pre).
Solid lines show group mean, dotted show individual data. Black line is the
mean for the entire group. We note that approximately half of participants are
responders, with a mean increase of greater than 200% post versus pre.

plasticity in the contralesional hemisphere in those with chronic
hemiparetic stroke.

Effect of PAS Off-Drug
MEP amplitude was raised over the 60 min post-intervention
relative to baseline, with the most consistent effect across
participants occurring 20 min post-intervention. Delayed peak
after-effects have been previously reported (Müller-Dahlhaus
et al., 2010). Variation in both the time-course and magnitude
of the PAS response could be influenced by factors including
disease state, lesion location, and concurrent medications. Stroke
patients typically have comorbidities (Ostwald et al., 2006),
managed with medications that may affect the response to
TMS (Siebner and Ziemann, 2007; Ziemann et al., 2014). In
our sample, thirteen of the fourteen participants were taking
drugs known to affect the response to brain stimulation,
or medications that have a similar neuro-pharmacological
mechanism of action to such drugs, including SSRI for the
treatment of depression (Siebner and Ziemann, 2007), and
anti-spasticity medication such as baclofen (Ziemann et al.,
2014). PAS response may also be influenced by genotyperelated differences such as BDNF and COMT polymorphism
interactions (Witte et al., 2012). Experimentally, we aimed to
reduce predicted variability in the quantified response by (a)
using a greater sample of MEPs post-intervention, which we have
previously shown can increase the sensitivity for detecting MEP
amplitude change (Bastani and Jaberzadeh, 2012), and (b) by
adjusting stimulus intensity to half-maximum MEP amplitude
at baseline, thus accounting for individual differences and
potential ceiling effects in contralesional hemisphere excitability.
Although inter-subject response variation is characteristic in
non-invasive neuromodulation (Wiethoff et al., 2014; Murase
et al., 2015; Schambra et al., 2015), our observed variation in MEP
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Stability of Electrophysiological and
Clinical Measures
We did not observe significant changes in RMT, sensory
perception, or motor function across the study period, indicating
that both escalating drug dose, as well as weekly PAS
intervention, had no cumulative effect on these measures.
RMT, the individually adjusted minimum stimulator output
required to elicit consistent MEPs, did not change regardless
of the memantine dose, indicating high test–retest reliability
and no effect of drug on this measure. RMT is thought to
represent neuronal membrane excitability, since it is increased
by drugs that block voltage-gated sodium channels such as
carbamazepine (Ziemann et al., 1996), and is not affected by
drugs influencing glutamatergic synapse activity such as riluzole
(Liepert et al., 1997). Stable RMT across the study period was
important experimentally, as threshold-adjusted PAS stimulus
intensity remained constant, providing validity for betweendose comparisons.
Somatosensory perceptual threshold for peripheral nerve
stimulation did not change across the 5 weeks of repeated PAS
and daily memantine administration, indicating a neutral effect
of memantine on sensory-afferent awareness and precision in
detection of peripheral stimuli. There was no change in measures
of impairment (Fugl-Meyer scale) or function (Wolf motor
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PAS-induced plasticity, since the RMT was not reduced (hyperexcitable) in relation to our prior studies in chronic stroke
(Schambra et al., 2015), and was comparable in both responder
and non-responder participants.
While our sample size may not be large, one must appreciate
the extent of the investigation that was conducted. This study
comprised a total of seventy PAS sessions, each involving the
collection of 96 MEPs. This represents one of the largest trials
utilizing PAS in the stroke population, with the exception
of a single study examining PAS as a potential therapeutic
intervention for stroke recovery (Tarri et al., 2018). An aim of this
investigation was to explore PAS as a potential screening method
for drugs of interest in neurorehabilitation, prior to investing
additional time and resources in a more extensive trial. Our
results neither support nor preclude the use of PAS as an effective
screening tool for drug effects on plasticity. Further investigation
is warranted to determine whether the observations gleaned from
this trial are the results of homeostatic metaplasticity.
Since PAS-induced excitability modulation is thought involve
the NMDA receptor, as supported by our results with memantine,
future studies in a stroke population could test the effects of other
commonly used agents acting on the NMDA receptor, specifically
with drugs that enhance activation of the NMDA receptor
complex such as D-cycloserine (Lanthorn, 1994), or a newer
generation of memantine, nitromemantine (Takahashi et al.,
2015). The specific strategy advocated here was to determine
the optimal dose for stimulating plasticity in the human brain
by using PAS potentiation as a surrogate marker of enhanced
plasticity. For example, PAS may have been useful to identify
whether the dose of D-cycloserine employed was optimal before
the longitudinal intervention trial in stroke rehabilitation (Butler
et al., 2015) which did not show a drug benefit.
Here, we studied a chronic stroke population, though
our approach could be applied in the early post-stroke
period to examine impact on plasticity with emerging
neuroprotective/neuroplasticity agents such as NA-1 (TatNR2B9c), an inhibitor of postsynaptic density-95 protein (Hill
et al., 2012; Dobkin, 2017), or maraviroc, a CCR5 antagonist
(Sorce et al., 2010). The use of PAS as plasticity marker
should be contingent upon the reproducibility of studies of
PAS in stroke. We recommend first assessing response to
PAS and reproducibility prior to an individual entering the
drug arm of a study.
Finally, while our finding of PAS corticospinal excitability
enhancement serves as a motor domain specific effect that might
be useful in post-stroke hemiparesis, PAS could plausibly be a
surrogate for drug-effects on plasticity in non-motor domains.

function test), thus clinical motor status remained stable over
the study period. The weekly dexterity and strength measures
also did not significantly vary. Taken together, these findings
indicate that while PAS plasticity is not observed in the presence
of memantine, there was no appreciable disruption to functional
performance in either the PAS-targeted hand (unaffected) or the
affected hand of chronic stroke patients, associated with weekly
escalating dose of memantine, and repeated exposure to PAS.

Exploratory Responder Analysis
In the present study, approximately 57% of participants were
classified as responders to PAS based on their response in the offdrug condition, which is consistent with other studies, at slightly
above 50% (Müller-Dahlhaus et al., 2008; Lahr et al., 2016). We
found that stroke symptom severity (measured by grip strength
and WMFT) and absence of MEP in the lesioned hemisphere
were predictors of response to PAS in the contralesional
hemisphere, where baseline excitability was comparable across
participants. This pattern of clinical and neurophysiological
features associated with responsiveness to PAS is consistent with
results described by Ferris et al. (2018). Plasticity induction
occurred more readily in the contralesional hemisphere of more
severe stroke patients, which could plausibly be due to a greater
propensity for hyperexcitability in the contralesional hemisphere.
We note that the degree of MEP amplitude increase postintervention in our responder population (mean 100–300%) was
higher than previous reports in the literature for healthy subjects,
which ranges from 20 to 78% (Ziemann et al., 2004; Fratello
et al., 2006; Müller-Dahlhaus et al., 2008; Ceccanti et al., 2018).
However, the relatively scarce studies of PAS response in stroke
subjects describe a wider range of response variability, with MEP
facilitation ranging from 40% to over 300% (Castel-Lacanal et al.,
2009; Palmer et al., 2018). We observed that five of the eight
responders in our population were taking SSRI medications,
which have been reported to enhance single pulse MEP amplitude
(Siebner and Ziemann, 2007) as well as augment PAS effects
(Batsikadze et al., 2013).
The effect of memantine was observed in both the PAS
responder (more clinically affected) and non-responder (less
clinically affected) groups. However, if a plasticity-enhancing
drug could be beneficial for a subgroup of patients who are more
severely affected but more susceptible to plasticity, this could have
important implications in stroke recovery and improve precision
in therapeutic prescription.

Limitations and Future Directions
As we tested the contralesional hemisphere, it is possible that
a differential effect of memantine occurs in the ipsilesional
hemisphere. We pursued to study the contralesional hemisphere
due to concerns of reliability and validity of the PAS protocol
in the ipsilesional hemisphere, as per Ferris et al. (2018).
Reduced efferent and/or afferent conduction, or absent response
completely, could impact the effectiveness of PAS, which is
considered to be dependent on a narrow window of arrival
of the peripheral stimulus afferent volley with the transcranial
motor cortex stimulation. Our current findings suggest that
the contralesional hemisphere is a suitable target for assessing
Frontiers in Neuroscience | www.frontiersin.org

CONCLUSION
We report the first study using non-invasive neuromodulation
to assay plasticity in the post-stroke human motor system for
the purpose of testing a clinically used neuroplasticity drug with
potential utility in neurorehabilitation. We showed that PAS is
effective for increasing corticospinal output in the contralesional
hemisphere in chronic post-stroke upper limb paresis, and may
serve as an assay for CNS target engagement for drugs of interest
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data interpretation, and literature search. RR: study design,
writing, data interpretation, and literature search. TK: writing,
data interpretation, and literature search. MI: study design,
writing, data interpretation, protocol revisions, figures, literature
search, and figures. BD and AW: study design, writing, data
interpretation, protocol revisions, and literature search. DE:
study design, writing, data interpretation, data analysis, protocol
revisions, figures, and literature search.

in post-stroke motor recovery. Applying this model to test a
candidate drug, memantine, we found that memantine blocked
PAS-induced plasticity, indicating CNS target engagement, but
our findings do not support the use of memantine at the doses
tested for enhancing motor system plasticity for rehabilitation.
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